BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

253 related articles for article (PubMed ID: 8153291)

  • 1. Liposomal amphotericin B (AmBisome) in Mediterranean visceral leishmaniasis: a multi-centre trial.
    Davidson RN; Di Martino L; Gradoni L; Giacchino R; Russo R; Gaeta GB; Pempinello R; Scott S; Raimondi F; Cascio A
    Q J Med; 1994 Feb; 87(2):75-81. PubMed ID: 8153291
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Short-course treatment of visceral leishmaniasis with liposomal amphotericin B (AmBisome).
    Davidson RN; di Martino L; Gradoni L; Giacchino R; Gaeta GB; Pempinello R; Scotti S; Cascio A; Castagnola E; Maisto A; Gramiccia M; di Caprio D; Wilkinson RJ; Bryceson AD
    Clin Infect Dis; 1996 Jun; 22(6):938-43. PubMed ID: 8783690
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [First-line liposomal amphotericin B for pediatric visceral leishmaniasis in southern France].
    Minodier P; Robert S; Noël G; Blanc P; Retornaz K; Garnier JM
    Arch Pediatr; 2005 Jul; 12(7):1102-8. PubMed ID: 15964525
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A 6 day course of liposomal amphotericin B in the treatment of infantile visceral leishmaniasis: the Italian experience.
    Cascio A; di Martino L; Occorsio P; Giacchino R; Catania S; Gigliotti AR; Aiassa C; Iaria C; Giordano S; Colomba C; Polara VF; Titone L; Gradoni L; Gramiccia M; Antinori S
    J Antimicrob Chemother; 2004 Jul; 54(1):217-20. PubMed ID: 15150166
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Parasite susceptibility to amphotericin B in failures of treatment for visceral leishmaniasis in patients coinfected with HIV type 1 and Leishmania infantum.
    Lachaud L; Bourgeois N; Plourde M; Leprohon P; Bastien P; Ouellette M
    Clin Infect Dis; 2009 Jan; 48(2):e16-22. PubMed ID: 19093811
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Limited effectiveness of high-dose liposomal amphotericin B (AmBisome) for treatment of visceral leishmaniasis in an Ethiopian population with high HIV prevalence.
    Ritmeijer K; ter Horst R; Chane S; Aderie EM; Piening T; Collin SM; Davidson RN
    Clin Infect Dis; 2011 Dec; 53(12):e152-8. PubMed ID: 22016502
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Treatment of paediatric visceral leishmaniasis: amphotericin B or pentavalent antimony compounds?
    Kafetzis DA; Velissariou IM; Stabouli S; Mavrikou M; Delis D; Liapi G
    Int J Antimicrob Agents; 2005 Jan; 25(1):26-30. PubMed ID: 15620822
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy and safety of liposomal amphotericin B (AmBisome) for visceral leishmaniasis in endemic developing countries.
    Berman JD; Badaro R; Thakur CP; Wasunna KM; Behbehani K; Davidson R; Kuzoe F; Pang L; Weerasuriya K; Bryceson AD
    Bull World Health Organ; 1998; 76(1):25-32. PubMed ID: 9615494
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Liposomal amphotericin B for complicated visceral leishmaniasis (kala-azar) in eastern Sudan: how effective is treatment for this neglected disease?
    Salih NA; van Griensven J; Chappuis F; Antierens A; Mumina A; Hammam O; Boulle P; Alirol E; Alnour M; Elhag MS; Manzi M; Kizito W; Zachariah R
    Trop Med Int Health; 2014 Feb; 19(2):146-52. PubMed ID: 24433217
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Liposomal amphotericin B for the treatment of visceral leishmaniasis.
    Bern C; Adler-Moore J; Berenguer J; Boelaert M; den Boer M; Davidson RN; Figueras C; Gradoni L; Kafetzis DA; Ritmeijer K; Rosenthal E; Royce C; Russo R; Sundar S; Alvar J
    Clin Infect Dis; 2006 Oct; 43(7):917-24. PubMed ID: 16941377
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Activity of liposomal amphotericin B (AmBisome) against Leishmania infantum and tissue distribution in mice.
    Gradoni L; Davidson RN; Orsini S; Betto P; Giambenedetti M
    J Drug Target; 1993; 1(4):311-6. PubMed ID: 8069573
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Amphotericin B therapy in children with visceral leishmaniasis: daily vs. alternate day, a randomized trial.
    Singh UK; Prasad R; Jaiswal BP; Singh PK; Thakur CP
    J Trop Pediatr; 2010 Oct; 56(5):321-4. PubMed ID: 20065047
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Visceral leishmaniasis in HIV infected patients: treatment with high dose liposomal amphotericin B (AmBisome).
    Russo R; Nigro LC; Minniti S; Montineri A; Gradoni L; Caldeira L; Davidson RN
    J Infect; 1996 Mar; 32(2):133-7. PubMed ID: 8708370
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Randomized double-blind study of liposomal amphotericin B (Ambisome) prophylaxis of invasive fungal infections in bone marrow transplant recipients.
    Tollemar J; Ringdén O; Andersson S; Sundberg B; Ljungman P; Tydén G
    Bone Marrow Transplant; 1993 Dec; 12(6):577-82. PubMed ID: 8136741
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Single-dose liposomal amphotericin B in the treatment of visceral leishmaniasis in India: a multicenter study.
    Sundar S; Jha TK; Thakur CP; Mishra M; Singh VP; Buffels R
    Clin Infect Dis; 2003 Sep; 37(6):800-4. PubMed ID: 12955641
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Visceral leishmaniasis in renal transplant recipients: successful treatment with liposomal amphotericin B (AmBisome).
    Boletis JN; Pefanis A; Stathakis C; Helioti H; Kostakis A; Giamarellou H
    Clin Infect Dis; 1999 Jun; 28(6):1308-9. PubMed ID: 10451172
    [TBL] [Abstract][Full Text] [Related]  

  • 17. U.S. Food and Drug Administration approval of AmBisome (liposomal amphotericin B) for treatment of visceral leishmaniasis.
    Meyerhoff A
    Clin Infect Dis; 1999 Jan; 28(1):42-8; discussion 49-51. PubMed ID: 10028069
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Liposomal amphotericin B as first line and secondary prophylactic treatment for visceral leishmaniasis in a patient infected with HIV.
    Borrelli P; Imperato A; Murdaca G; Scudeletti M
    Ann Ital Med Int; 2000; 15(2):169-71. PubMed ID: 10920508
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Liposomal amphotericin B for visceral leishmaniasis in human immunodeficiency virus-coinfected patients: 2-year treatment outcomes in Bihar, India.
    Sinha PK; van Griensven J; Pandey K; Kumar N; Verma N; Mahajan R; Kumar P; Kumar R; Das P; Mitra G; Flevaud L; Ferreyra C; Remartinez D; Pece M; Palma PP
    Clin Infect Dis; 2011 Oct; 53(7):e91-8. PubMed ID: 21890763
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Single-dose liposomal amphotericin B for visceral leishmaniasis in India.
    Sundar S; Chakravarty J; Agarwal D; Rai M; Murray HW
    N Engl J Med; 2010 Feb; 362(6):504-12. PubMed ID: 20147716
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.